Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ENERGI F703

Next Previous
Drug Profile

ENERGI F703

Alternative Names: ENERGIF703

Latest Information Update: 10 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Energenesis Biomedical
  • Class Foot disorder therapies; Skin disorder therapies
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic foot ulcer
  • Phase II Varicose ulcer

Most Recent Events

  • 30 May 2023 Phase-III clinical trials in Diabetic foot ulcer in USA (Topical) (NCT05930210)
  • 26 Jul 2022 Phase-II clinical trials in Varicose ulcer (In adults, In the elderly) in Taiwan (Topical) (NCT04078555)
  • 25 Jun 2021 Efficacy and adverse events data from a phase II trial in Diabetic foot ulcer presented at the 81st Annual Scientific Sessions of the American Diabetes Association (ADA-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top